REFERENCES
- Buhring, K. U., Diekmann, H. W., Muller, H., Garbe, A. & Nowak, H. (1978). Metabolism of praziquantel in man. European Journal of Drug Metabolism and Pharmacokinetics, 3, 179–190.
- Bundy, D. P., Chandiwana, S. K., Homeida, M. M. A., Yoon, S. & Mott, K. (1991). The epidemiological implications of a multiple-infection approach to the control of helminth infections. Transactions of the Royal Society of Tropical Hygiene, 85, 274–276.
- Chen, M. G., Fu, S., Hua, X. J., Wu, H. M. (1983). A retrospective survey of side effects of praziquantel among 25 693 cases of schistosomiasis japonica. South-East Asian Journal of Tropical Medicine and Public Health, 14, 495–500.
- Frohberg, H. (1984). Results of toxicological studies with praziquantel. Arzneimittel-Forschung, 34, 1137–44.
- Frohberg, H. (1989). The toxicological profile of praziquantel in comparison to other antihelmintic drugs. Acta Leidensia, 57, 201–215.
- Jung, H., Hurtado, M., Medina, M. T., Sanchez, M., Sotelo, J. (1990). Dexamethazone increases plasma levels of albendazole. Journal of Neurology, 237, 279–280.
- King, C. H. & Mahmoud, A. A. F. (1989). Drugs five years later: praziquantel. Annals of Internal Medicine, 110, 290–296.
- Lange, H., Eggers, R. & Bircher, J. (1988). Increased systemic availability of albendazole when taken with a fatty meal. European Journal of Clinical Pharmacology, 34, 315–317.
- Leopold, G., Unguthem, W., Groll, E., Diekmann, H. W., Nowak, H. & Wegner, D. H. G. (1978). Clinical pharmacology in normal volunteers of praziquantel. A new drug against schistosomes and cestodes. European Journal of Clinical Pharmacology, 14, 281–291.
- Mandour, M. E. M., El Turabi, H., Homeida, M. M. A., El Sadig, T., Ali, H. M., Bennett, J. L., Leahey, W. J., & Harron, D. W. G. (1990). Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, 389–393.
- Marreiner, S. E., Morris, D. L., Dickson, B. & Bogan, J. A. (1986). Pharmacokinetics of albendazole in man. European Journal of Clinical Pharmacology, 30, 705–708.
- Munst, G. J., Karlanganis, G. & Bircher, J. (1980). Plasma concentrations of mebendazole during treatment of echinococcosis. European Journal of Clinical Pharmacology, 17, 375–378.
- Overbosch, D. (1992). Neurocysticercosis. An introduction with special emphasis on new development in pharmacotherapy. Journal Suisse de Médicine, 122, 893–898.
- Patzschke, K., Putter, J., Wegner, L. A., Horster, F. A. & Diekmann, H. W. (1979). Serum concentrations and renal excretion in humans after oral administration of praziquantel. Results of three determination methods. European Journal of Drug Metabolism and Pharmacokinetics, 3, 149–156.
- Penicaut, B., Maugein, P., Maisonneuve, H. & Rossignol, J. F. (1983). Pharmacokinetics and urinary metabolism of albendazole in man. Bulletin de la Société de Pathologic Exotiques et de ses Filiales, 76, 698–708.
- Reynoldson, J. A., Thompson, R. C. A. & Horton, R. T. (1992). Albendazole as a future antigiardial agent. Parasitology Today, 8, 412–414.
- Waring, R. M., Mitchell, S. C., Shah, R. A., Idle, J. R. & Smith, R. L. (1982). Polymorphic sulphoxidation of S-carboxylmethyl-l-cysteine in man. Biochemical Pharmacology, 31, 3151–3154.
- Watt, G., White, N. J., Padre, L., Ritter, W., Fernando, M. T., Ranoa, C. P. & Laughlin, L. W. (1988). Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease. Journal of Infectious Diseases, 157, 530–535.